PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$134.40

30 Apr
2026

-0.440

OPEN

$134.17

-0.33%

HIGH

$136.78

391,530

LOW

$133.01

TARGET
$224.167 66.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 110.3 182.2 xxx
DPS (cps) xxx 55.0 67.2 xxx
EPS Growth xxx 39.1% 65.3% xxx
DPS Growth xxx 37.5% 22.1% xxx
PE Ratio xxx N/A 74.7 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 49.9% 36.9% xxx

Dividend yield today if purchased 3 years ago: 0.90%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.40

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 30.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx110.3
DPS All xxxxxxxxxxxxxxx55.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx246.0
Net Operating Cash Flow xxxxxxxxxxxxxxx118.9 M
Net Profit Margin xxxxxxxxxxxxxxx54.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx51.82 %
Return on Invested Capital xxxxxxxxxxxxxxx51.46 %
Return on Assets xxxxxxxxxxxxxxx38.65 %
Return on Equity xxxxxxxxxxxxxxx51.82 %
Return on Total Capital xxxxxxxxxxxxxxx70.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx69.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx209 M
Price To Book Value xxxxxxxxxxxxxxx115.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxxxxxxxx3.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

07/04/2026

1

Buy

$245.00

82.29%

Citi highlights Pro Medicus shares have fallen some circa -50% year-to-date, and the analyst adjusts earnings forecasts for the roll-on of already won business to the latter part of the 2H26 and into FY27, and updates USDAUD currency assumptions (negligible impact).

The company announced around a 10% share buyback last week, with around $150m worth of shares to be acquired through to the end of FY27, well below the announced allowance of around $1bn.

Adjusting for the "push out" in sales, the valuation falls to $245 per share. Citi believes Pro Medicus' moat remains intact and is difficult to copy, with its customers "better off than without" its products.

Whether the new target price of $245, down from $300, is reached very much depends on investors' disposition to own SaaS businesses, as well as the specific characteristics of Pro Medicus' business, the analyst explains. Buy rated.

FORECAST
Citi forecasts a full year FY26 dividend of 69.00 cents and EPS of 288.80 cents.
Citi forecasts a full year FY27 dividend of 91.30 cents and EPS of 182.70 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

13/02/2026

1

Buy

$180.82

34.54%

Following interim results for Pro Medicus, Canaccord Genuity lowers its target to $180.82 from $350.00, partly due to a new take from replacement analyst Madelaine Williams.

The broker's medium-term revenue downgrades reflect revised assumptions for new contract wins and a more measured pace of market penetration.

Interim revenue of $124.8m rose 28%, though modestly below the analysts' forecast, while margins expanded. Total contracted value stands at $1.08bn, with the Trinity contract ramping from October 2026.

The business is fundamentally sound, according to the broker, with AI concerns viewed as overstated given long-term contracts and integration optionality.

Competitive dynamics are evolving, the analysts observe, but medium-term growth remains supported by US penetration and adjacent modalities.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 74.00 cents and EPS of 247.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 99.00 cents and EPS of 198.00 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia